45121-22-0

Basic information

• Product Name: BOC-D-ABU-OH
• Synonyms: BOC-D-NHCH(CH2CH3)-COOH;BOC-D-AMINOBUTYRIC ACID;BOC-D-ALPHA-ABU-OH;BOC-D-ALPHA-AMINOBUTYRIC ACID;BOC-D-ABU(2)-OH;BOC-D-ABU(ALPHA)-OH;BOC-D-ABU-OH;BOC-D-2-AMINOBUTYRIC ACID
• CAS NO: 45121-22-0
• Molecular Formula: C₉H₁₇NO₄
• Molecular Weight: 203.24
• Mol File: 45121-22-0.mol

Chemical Properties

• Boiling Point: 334.517 °C at 760 mmHg
• Flash Point: 156.11 °C
• Appearance: Yellow/Liquid
• Density: 1.101
• Storage Temp.: Store at RT.
• Solubility: Soluble in DMF (1mmol in 1ml DMF).
• PKA: 4.00±0.10(Predicted)
• CAS DataBase Reference: BOC-D-ABU-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-ABU-OH(45121-22-0)
• EPA Substance Registry System: BOC-D-ABU-OH(45121-22-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 45121-22-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
BOC-D-ABU-OH is used as a coupling agent in chemical synthesis for its ability to facilitate the formation of new chemical bonds between molecules. This property is particularly valuable in the creation of complex organic compounds and pharmaceuticals.
Used in Dye Preparation:
In the dye industry, BOC-D-ABU-OH is used as a key component in the preparation of various dyes. Its chemical structure contributes to the development of dyes with specific color properties and stability, making it an essential ingredient in the production process.
Used in Pharmaceutical Industry:
BOC-D-ABU-OH is also utilized in the pharmaceutical industry, where its coupling properties are harnessed to synthesize new drugs and improve the efficacy of existing medications. Its versatility in chemical reactions allows for the development of a wide range of therapeutic compounds.
Used in Research and Development:
Due to its unique chemical properties, BOC-D-ABU-OH is often employed in research and development settings. Scientists and researchers use this compound to explore new reaction pathways, develop innovative materials, and study the fundamental principles of chemical interactions.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 40522-79-0 2-aminobutyric acid hydrochloride 
• 162107-49-5 (R)-tert-butyl (1-hydroxybut-3-yn-2-yl)carbamate 
• 185509-01-7 (S,S)-pseudoephedrine N-Boc-2-D-aminobutyramide 
• 170642-21-4 (S,S)-pseudoephedrine D-2-aminobutyramide 
• 162107-50-8 N-Boc-D-ethynyl glycine 
• 2835-81-6 2-aminobutanoic acid 

Downstream Products

• 145280-04-2 (1R,2S,5R)-2-(1-methyl-1-phenylethyl)-5-methylcyclohexyl (S)-2-<(tert-butoxycarbonyl)amino>butanoate 
• 145280-03-1 (1R,2S,5R)-2-(1-methyl-1-phenylethyl)-5-methylcyclohexyl (R)-2-<(tert-butoxycarbonyl)amino>butanoate 
• 786652-81-1 [1-(1-methyl-2-oxo-2-phenyl-ethylcarbamoyl)-propyl]carbamic acid tert-butyl ester 
• 162126-54-7 (R)-2-(t-butoxycarbonylamino)-N-phenyl-butanamide 
• 1397708-99-4 C₂₃H₂₈N₄O₄ 
• 1403942-29-9 (S)-tert-butyl 1-oxo-1-(2-(phenylcarbamoyl)-1H-pyrrol-1-ylamino)butan-2-ylcarbamate 
• 58561-08-3 methyl N-(tert-butoxycarbonyl)-2-aminobutyrate 
• 34306-42-8 Boc-Abu 
• 75244-11-0 N^α-tosyl-N^γ-(tert-butyloxycarbonyl-D-aminobutyryl)-L-diaminobutyric acid benzyl ester 
• 160581-25-9 Boc-D-Abu-N-MeArg(Tos)-Gly-OBzl 
• 160581-25-9 C₃₂H₄₆N₆O₈S 
• 406938-50-9 Boc-N-D-Abu-L-(Ph)Sec-Sar-OEt 

Relevant articles and documents

Enantioselective Deaminative Alkylation of Amino Acid Derivatives with Unactivated Olefins

Herein, we report the first Ni-catalyzed enantioselective deaminative alkylation of amino acid and peptide derivatives with unactivated olefins. Key for success was the discovery of a new sterically encumbered bis(oxazoline) ligand backbone, thus offering a de novo technology for accessing enantioenriched sp3-sp3 linkages via sp3 C-N functionalization. Our protocol is distinguished by its broad scope and generality across a wide number of counterparts, even in the context of late-stage functionalization. In addition, an enantioselective deaminative remote hydroalkylation reaction of unactivated internal olefins is within reach, thus providing a useful entry point for forging enantioenriched sp3-sp3 centers at remote sp3 C-H sites.

Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection

Due to the increased morbidity and mortality by fungal infections and the emergence of severe antifungal resistance, there is an urgent need for new antifungal agents. Here, we screened for antifungal activity in our in-house library through the minimum inhibitory concentration test and derived two hit compounds with moderate antifungal activities. The hit compounds' antifungal activities and drug-like properties were optimized by substituting various aryl ring, alkyl chain, and methyl groups. Among the optimized compounds, 22h was the most promising candidate with good drug-like properties and exhibited potent fast-acting fungicidal antifungal effects against various fungal pathogens and synergistic antifungal activities with some known antifungal drugs. Additionally, 22h was further confirmed to disturb fungal cell wall integrity by activating multiple cell wall integrity pathways. Furthermore, 22h exerted significant antifungal efficacy in both the subcutaneous infection mouse model and ex vivo human nail infection model.

FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to novel functional derivatives of alanine and proline amino acids. The compounds of the present invention were confirmed to have a very superior antifungal or fungicidal effect. In addition, the compounds of the present inve

HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases.

Bioproduction of l-2-Aminobutyric Acid by a Newly-Isolated Strain of Aspergillus tamarii ZJUT ZQ013

Abstract: l-2-Aminobutyric acid (l-ABA), an unnatural amino acid, is a key intermediate of several important drugs. Although some methods have been developed to prepare pure chiral l-ABA, there are still many drawbacks, including low catalytic efficiency, cumbersome steps and high cost due to the addition of some expensive catalysts or coenzymes. Herein, with chemical and biological approaches together, we discovered a newly isolated Aspergillus tamarii ZJUT ZQ013 strain containing a microbial lipase which could be employed to resolve racemic methyl N-Boc-2-aminobutyrate to produce l-ABA with high enantioselectivity (e.e.s?>?99.9%, E = 257). Moreover, the subsequent gram scale experiment confrimed that A. tamarii ZJUT ZQ013 could be an attractive biocatalyst for the efficient preparation of optically pure acid. Graphical Abstract: [Figure not available: see fulltext.]

Pinensins: The First Antifungal Lantibiotics

Lantibiotics (lanthionine-containing antibiotics) from Gram-positive bacteria typically exhibit activity against Gram-positive bacteria. The activity and structure of pinensin A (1) and B (2), lantibiotics isolated from a native Gram-negative producer Chitinophaga pinensis are described. Surprisingly, the pinensins were found to be highly active against many filamentous fungi and yeasts but show only weak antibacterial activity. To the best of our knowledge, lantibiotic fungicides have not been described before. An in-depth bioinformatic analysis of the biosynthetic gene cluster established the ribosomal origin of these compounds and identified candidate genes encoding all of the enzymes required for post-translational modification. Additional encoded functions enabled us to build up a hypothesis for the biosynthesis, export, sensing, and import of this intriguing lantibiotic.

Highly practical methodology for the synthesis of D- and L-α-amino acids, N-protected α-amino acids, and N-methyl-α-amino acids

Full details are provided for an exceedingly practical method to synthesize D- and L-α-amino acids, N-protected α-amino acids, and N-methyl-α-amino acids, employing as a key step the asymmetric alkylation of pseudoephedrine glycinamide (1) or pseudoephedrine sarcosinamide (2). Practical procedures for the synthesis of 1 and 2 from pseudoephedrine and glycine methyl ester or sarcosine methyl ester, respectively, are presented. Optimum protocols for the enolization and subsequent alkylation of 1 and 2 are described. Alkylation reactions of 1 and 2 are found to be quite efficient with a wide range of alkyl halide substrates, and the products are formed with high diastereoselectivity. The products of these alkylation reactions are hydrolyzed efficiently and with little to no racemization simply by heating in water or water-dioxane mixtures. This protocol provides an exceedingly practical method for the preparation of salt-free α-amino acids of high enantiomeric purity. Alternatively, the alkylation products may be hydrolyzed in high yield and with little to no racemization by heating with aqueous sodium hydroxide. The alkaline hydrolyzate can then be treated with an acylating reagent to provide directly highly enantiomerically enriched N-protected derivatives such as N-Boc and N-Fmoc. Key features necessary for the successful execution of these experimental procedures are identified.

Synthesis of optically active β,γ-alkynylglycine derivatives

Full results on the first synthesis of optically active β,γ-alkynylglycine derivatives from naturally occurring L-serine are described. The methodology uses L-serinal as a key intermediate and allows great versatility in the introduction of N-protective groups and of alkyne substitution. The N-Boc protected β,γ-alkynylglycine derivatives described have ee greater than 90%.

En route to optically active ethynylglycine derivatives

First results in the synthesis of chiral non racemic ethynylglycine derivatives from protected L-serinal are described.